Targeting cellular plasticity to prevent and treat chemotherapy-resistant disease
Targeting cellular plasticity to prevent and treat chemotherapy-resistant disease
Dr Beatriz Perez San JuanThe Garvan Institute of Medical Research$368,9122023-2025
Background
Triple-negative breast cancer (TNBC) is an aggressive type of cancer that accounts for around 20% of cases. There are no treatments that specifically target this form of breast cancer,so it commonly recurs after initial treatment, spreading to other areas of the body.Chemotherapy is the only treatment option, but for up to 35% of women with triple negative breast cancerchemotherapy will fail to have any significant impact. For those women, palliative care is the only treatment approach that remains. New treatment options for triple negative breast cancer are urgently needed to improve treatment and survival outcomes.
The research
Dr Beatriz Perez San Juan’sresearchis focussed on developing new targeted treatments for triple negative breast cancer that overcome the challenge of chemotherapy failure.
